Prescription drug · NDA
UPTRAVI Titration Pack (selexipag) NDC 66215-628
Kit · Actelion Pharmaceuticals US, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 66215-628-20 | 66215062820 | 1 KIT in 1 CARTON (66215-628-20) * 1 BOTTLE in 1 CARTON / 140 TABLET, COATED in 1 BOTTLE * 1 BOTTLE in 1 CARTON / 60 TABLET, COATED in 1 BOTTLEMarketed from Dec 21, 2015 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- UPTRAVI Titration Pack
- Generic name (nonproprietary)
- selexipag
- Dosage form
- Kit
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 207947
- Marketing start
- Listing expires
- Identifiers
- Product ID 66215-628_7c54a125-9778-41f5-b92c-181711e22e06SPL ID 7c54a125-9778-41f5-b92c-181711e22e06SPL set ID a7a23b87-f892-4e2c-8e2e-ebf841220f90RxCUI 1729007, 1729013, 1729027, 1729029, 1729031, 1729033, 1729045, 1729047, 1729051, 1729053, 1729055, 1729057, 1729059, 1729061, 1729063, 1729065, 1729075, 1729076, 2565271, 2565275, 2744282, 2744284, 2744286, 2744288UNII 5EXC0E384LUPC 0366215612064, 0366215610060, 0366215604069, 0366215910146, 0366215606063, 0366215614068, 0366215616062
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N466215062820followed by a unit qualifier and the quantityPackage 66215-0628-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) In pediatric patients aged 2 years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) 1.1 Pulmonary Arterial Hypertension Adult Patients UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness of UPTRAVI tablets was established in a long-term study in ad…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 207947
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Uptraviselexipag | Selexipag 600 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-606 |
| Uptraviselexipag | Selexipag 200 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-602 |
| Uptraviselexipag | Selexipag 400 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-604 |
| Uptraviselexipag | Selexipag 1400 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-614 |
| Uptraviselexipag | Selexipag 800 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-608 |
| Uptraviselexipag | Selexipag 1000 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-610 |
| Uptraviselexipag | Selexipag 1200 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-612 |
| Uptraviselexipag | Selexipag 1600 ug/1 | Tablet, CoatedOral | Actelion Pharmaceuticals US, Inc. | 66215-616 |
| Uptraviselexipag | Selexipag 150 ug/1 | Tablet, Film coatedOral | Actelion Pharmaceuticals US, Inc. | 66215-915 |
| Uptraviselexipag | Selexipag 100 ug/1 | Tablet, Film coatedOral | Actelion Pharmaceuticals US, Inc. | 66215-910 |